While most antiangiogenic ECM fragments have yet to enter clinical development, three phase I trials have been published using recombinant human endostatin in a total of 61 patients with advanced metastatic cancer (including 11 melanoma, 10 sarcoma, nine colorectal, nine lung, seven breast, four renal) (Eder et al, 2002; Herbst et al, 2002a; Thomas et al, 2003). The gene discussed is COL18A1; the disease is melanoma.